drugset / Trial / NCT03781947
A Study of Parenterally-administered Teverelix TFA in Healthy Male Volunteers
Non-randomizedParallel-groupOpen-labelBasic science
Summary
A Phase I, open-label, single centre study investigating the pharmacokinetics, safety and pharmacodynamics of a single dose of teverelix TFA, a gonadotrophin releasing hormone antagonist, via subcutaneous or intramuscular route of administration in healthy male volunteers
Timeline
- Start
- 2018-11-19
- Primary completion
- 2020-03-16
- Completion
- 2020-03-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Teverelix | Protein / enzyme biologic | 60 mg | Subcutaneous |
| Subject | Teverelix | Protein / enzyme biologic | 90 mg | Subcutaneous |
| Subject | Teverelix | Protein / enzyme biologic | 120 mg | Subcutaneous |
Indications
No indication recorded.